openPR Logo

Press Releases from cerbomed GmbH (19 total)

Pharmaceuticals and medical technology will go hand in hand in future – DESITI …

ERLANGEN/HAMBURG, September 17th, 2015 – The medical technology company cerbomed GmbH from Erlangen and the pharmaceutical company DESITIN Arzneimittel GmbH from Hamburg have entered into a groundbreaking distribution agreement: DESITIN has been granted exclusive distribution rights in Germany by cerbomed for the transcutaneous vagus nerve stimulator NEMOS for treatment of epilepsy. The successful medium-sized independent company DESITIN has been a specialist provider and proficient partner to doctors and patients in the

transcutaneous Vagus Nerve Stimulation for epilepsies now available in Norway

ERLANGEN/DRAMMEN, May 28th, 2015 – To address the Norwegian market with transcutaneous Vagus Nerve Stimulation (t-VNS), the medical device company cerbomed from Erlangen, Germany, is cooperating with an experienced distribution partner: Scan-Med A/S from Drammen, Norway. The company, founded in 1982, considers itself as a connecting link between manufacturers of medical devices and hospitals, as well as health institutions and specialized on distribution service and support of medical equipment. “We are

Vagus nerve stimulation without surgery now available in Denmark, Finland and Sw …

ERLANGEN/AALBORG, Mai 28th, 2015 – More than 30 percent of all epilepsy patients still suffer from continued occurrence of seizures, despite appropriate treatment with anticonvulsive drugs. For these patients, only few treatment alternatives are available at the moment. One promising therapy option is transcutaneous Vagus Nerve Stimulation (t-VNS), now also available for patients in Denmark, Sweden and Finland. This has been made possible by cerbomed‘s new distributor Cephalon A/S.

Trial results for transcutaneous Vagus Nerve Stimulation in pharmacoresistant ep …

ERLANGEN/DRESDEN, 30th April 2015 – At the 9th annual joint conference of the three German-speaking regions of the International League Against Epilepsy in Dresden, the results of a trial on transcutaneous Vagus Nerve Stimulation (t-VNS) in pharmacoresistant epilepsy were presented for the first time. Trial shows reduction in seizures with t-VNS In the multi-centre, randomised, controlled, 2-arm, double-blind study, 76 adult epilepsy patients from Germany and Austria were treated over 5

Cerbomed GmbH at the 11th European Congress on Epileptology in Stockholm

ERLANGEN/STOCKHOLM, 30.06.2014 – From June 30th until July 3rd 2014 the medical device company cerbomed GmbH from Erlangen, Germany, will present a further therapy option for people suffering from epilepsies at the 11th European Congress on Epileptology in Stockholm: The transcutaneous Vagus Nerve Stimulation (t-VNS) with the therapy device NEMOS. About t-VNS with NEMOS Transcutaneous Vagus Nerve Stimulation with NEMOS offers a further therapy option to epilepsy

Cerbomed GmbH at the 30th International Congress of Clinical Neurophysiology

ERLANGEN/BERLIN, 13.03.2014 – From March 19th until 23rd 2014 the medical device company cerbomed GmbH from Erlangen, Germany, will present the transcutaneous Vagus Nerve Stimulation (t-VNS) at the 30th International Congress of Clinical Neurophysiology. Please save March 21st and use the chance to get additional information about t-VNS at the Lunch Symposium “Transcutaneous Vagus Nerve Stimulation (t-VNS). Treatment option in epilepsy and pain.” from 12:15 to 13:45 p.m. About

Cerbomed at the INS 11th World Congress in Berlin

ERLANGEN/BERLIN, Germany, June 6th 2013 – Between June 9th and 12th, 2013, the German medical device company cerbomed GmbH will present another therapy option for people suffering from hard-to-treat neurological and psychiatric diseases at the 11th world congress of the International Neuromodulation Society in Berlin: transcutaneous Vagus Nerve Stimulation (t-VNS). About t-VNS The t-VNS offers a therapy option for patients suffering from epilepsies, depression or pain. This therapy uses

Cerbomed GmbH at the 86th Congress of the German Society of Neurology

ERLANGEN/DRESDEN, Germany, September 12th, 2013 – At the 86th congress of the German Society of Neurology in Dresden the medical device company cerbomed GmbH, Erlangen, Germany, will present a further therapy option for patients suffering from hard-to-treat neurological and psychiatric illnesses: Between September 18th and 21st participants will get first-hand information about the transcutaneous Vagus Nerve Stimulation (t-VNS). About t-VNS The t-VNS offers a therapy option for patients suffering from epilepsies,

Cerbomed GmbH presents transcutaneous Vagus Nerve Stimulation at the 8th annual …

ERLANGEN/BERLIN, Germany, November 20th, 2012 – Between November 23rd and 24th, 2012 the medical device company cerbomed GmbH, Erlangen, Germany will present the transcutaneous Vagus Nerve Stimulation (t-VNS) at the 8th annual meeting of the German Society of Neuromodulation. Participants will get first-hand information about the new therapy option for patients suffering from difficult-to-treat epilepsies, depression and pain at the booth and in the course of a symposium on November

Cerbomed GmbH at the 35th Congress of the German Society of Neurology

ERLANGEN/HAMBURG, Germany, September 24th, 2012 – Between September 26th and 29th, 2012 the medical device company cerbomed GmbH from Erlangen, Germany will present the transcutaneous Vagus Nerve Stimulation (t-VNS) at the 35th congress of the German Society of Neurology in Hamburg. Participants will get first-hand information about the new therapy option for patients suffering from difficult-to-treat epilepsies, depression and pain. About t-VNS Transcutaneous Vagus Nerve Stimulation is addressed to

Cerbomed GmbH: Start of a multi-center trial into t-VNS for drug-resistant epile …

ERLANGEN/KEHL-KORK, June 21st, 2012 – the medical device company cerbomed GmbH, Erlangen, Germany and the Epilepsy Center Kork, Germany announce the inclusion of the first patient in a multi-center clinical trial into the treatment of drug-resistant epilepsy using transcutaneous Vagus Nerve Stimulation (t-VNS). This clinical trial, conducted in seven epilepsy centers in Germany and Austria, examines the effectiveness of t-VNS in treating drug-resistant epilepsy. The trial starts with the inclusion of

Cerbomed GmbH: First patient included in the chronic migraine trial

ERLANGEN/MUNICH, May 22nd, 2012 – The medical device company cerbomed GmbH, Erlangen, and the Headache Center of the Neurological Department at the Großhadern Hospital in Munich announce the inclusion of the first patient in the clinical trial for treating chronic migraine using transcutaneous Vagus Nerve Stimulation (t-VNS). Under the supervision of Prof. Dr. med. Andreas Straube, the study will examine the effectiveness and safety of t-VNS in a randomized, double-blind

A renewed web presence for cerbomed GmbH

ERLANGEN, Germany, March 8th, 2012 – The German medical device company cerbomed GmbH is re-launching its web site. At www.cerbomed.com patients and their families, as well as doctors, and medical specialists can access tailored information on transcutaneous Vagus Nerve Stimulation (t-VNS), using the device NEMOS. The new therapy alternative for difficult-to-treat epilepsies and depression will be available in Germany in summer 2012. The new web-presence marks cerbomed as a provider of

Cerbomed GmbH at the 10th annual meeting of the Austrian Society for Neurology ( …

ERLANGEN/GRAZ, Germany, Austria, March 8th, 2012 – Between March 14th and 17th, 2012 cerbomed GmbH will present the transcutaneous Vagus Nerve Stimulation (t-VNS) with NEMOS at the 10th annual meeting of the Austrian Society for Neurology in Graz. Participants will get the opportunity to get in touch with the new therapy option for patients suffering from difficult-to-treat epilepsies and depression. About t-VNS Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering

Cerbomed at the 51st annual conference of the German Society for Epileptology

ERLANGEN/STUTTGART, Germany, February 23rd, 2012 – Between February 29th and March 3rd, 2012 cerbomed GmbH will introduce the transcutaneous Vagus Nerve Stimulation (t-VNS) with NEMOS at the 51st annual conference of the German Society for Epileptology in Stuttgart. Participants will get the opportunity to inform themselves about the new therapy option at the booth and in the course of a symposium on March 1st. About t-VNS Transcutaneous Vagus Nerve Stimulation

Expertise in epilepsy treatment: Prof. Dr. med. Hajo Hamer reinforces the scient …

ERLANGEN, Germany, 21.02.2012 – In Prof. Dr. Hajo Hamer the medical device company cerbomed GmbH gains a renowned expert in epileptology for its scientific advisory board. Prof. Dr. Hamer will support cerbomed GmbH in carrying out an international multi-center study to treat drug-resistant epilepsy, using transcutaneous Vagus Nerve Stimulation (t-VNS). Since April 1st, 2011 Prof. Dr. Hamer has been the new head of the Epilepsy Center at the University Hospital,

Cerbomed at the 4th International Epilepsy Colloquium in Marburg

ERLANGEN, Germany, 24.06.2011 – The medical device company cerbomed GmbH is proud to present NEMOS, the world’s first medical device for transcutaneous Vagus Nerve Stimulation (t-VNS), at the 4th International Epilepsy Colloquium in Marburg from June 27th to 30th. Please save June 29th and use the chance to get additional information about t-VNS in the course of a presentation at the Post-Symposium „Brain Stimulation as Treatment Option for Epilepsy”. About

cerbomed gets CE labeling for transcutaneous vagus nerve stimulator

Erlangen, May 12th, 2010. cerbomed gmbh, a start-up company in the area of neuro-stimulation, today announced that its transcutaneous vagus nerve stimulator now has the CE label for use for the indications of depres-sion and epilepsy, and is approved for sale in the European Union. This milestone in the certification of the young enterprise clears the way for marketing and sales in the 25 EU member states. The transcutaneous vagus

cerboMed appoints Christoph A. Bally as Chief Executive Officer

Erlangen, Mai 30, 2009. cerboMed GmbH, a medical device company focused on innovative neurostimulation technologies, has appointed Christoph Bally as the company’s Chief Executive Officer (CEO). cerboMed GmbH from Erlangen, Germany, announces today that Christoph Bally has been appointed as the company’s Chief Executive Officer in order to further strengthen the existing management team of the two company founders, Stefan Dietrich and Timo Freitag. Christoph Bally will be able to contribute

Go To Page:   0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 -19 -18 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1